PMID- 30924071
OWN - NLM
STAT- MEDLINE
DCOM- 20191024
LR  - 20200225
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Print)
IS  - 0962-9343 (Linking)
VI  - 28
IP  - 9
DP  - 2019 Sep
TI  - Health state utilities associated with attributes of migraine preventive 
      treatments based on patient and general population preferences.
PG  - 2359-2372
LID - 10.1007/s11136-019-02163-3 [doi]
AB  - PURPOSE: While previous studies have estimated health state utilities associated 
      with migraine severity and frequency, migraine treatments vary in other ways that 
      may have an impact on patients' quality of life, preference, and utility. The 
      purpose of this study was to estimate utilities associated with migraine 
      treatment attributes including route of administration and treatment-related 
      adverse events (AEs). METHODS: In time trade-off interviews, migraine patients 
      and general population participants in the UK valued health state vignettes 
      drafted based on literature, medication labels, and clinician interviews. All 
      respondents valued migraine health states varying in route of administration. 
      Each participant also valued eight health states (randomly selected from a total 
      of 15) that added the description of an AE to a migraine health state. RESULTS: A 
      total of 400 participants completed interviews (200 general population [49.0% 
      female; mean age = 43.6 years]; 200 migraine patients [74.5% female; mean 
      age = 45.8 years]). In the general population sample, mean utilities of health 
      states without aura were 0.79 with daily oral medication, 0.78 with one injection 
      per month, and 0.72 with 31-39 injections once every 3 months. The greatest 
      disutilities (i.e., decreases in utility) were for AEs associated with oral 
      medications (e.g., - 0.060 [fatigue] and - 0.098 [brain fog]). Differences among 
      health states followed the same pattern in the patient sample as in the general 
      population sample. CONCLUSIONS: Utilities estimated from the general population 
      sample may be used to represent route of administration and AEs in cost-utility 
      models. Results from the patient sample indicate that these treatment 
      characteristics have an impact on patient preference.
FAU - Matza, Louis S
AU  - Matza LS
AD  - Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD, 20814, USA. Louis.matza@evidera.com.
FAU - Deger, Kristen A
AU  - Deger KA
AD  - Modeling and Simulation, Evidera, Bethesda, MD, USA.
FAU - Vo, Pamela
AU  - Vo P
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Maniyar, Farooq
AU  - Maniyar F
AD  - Basildon and Thurrock University Hospitals and Queen Mary University, London, UK.
FAU - Goadsby, Peter J
AU  - Goadsby PJ
AD  - NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, 
      London, UK.
LA  - eng
GR  - EVA-20287/Novartis Pharma AG/
PT  - Journal Article
DEP - 20190328
PL  - Netherlands
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of 
      treatment, care and rehabilitation
JID - 9210257
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Migraine Disorders/*prevention & control/therapy
MH  - Patient Preference/*psychology
MH  - Pilot Projects
MH  - Quality of Life/*psychology
PMC - PMC6698266
OTO - NOTNLM
OT  - Adverse events
OT  - Migraine
OT  - Route of administration
OT  - Time trade-off
OT  - Treatment process utilities
OT  - Utility
COIS- Louis S. Matza and Kristen A. Deger are employees of Evidera, a company that 
      received funding from Novartis for time spent conducting this research. Pamela Vo 
      is an employee of Novartis Pharma AG. Farooq Maniyar and Peter J. Goadsby 
      received payment from Novartis for time spent on this research.
EDAT- 2019/03/30 06:00
MHDA- 2019/10/28 06:00
PMCR- 2019/03/28
CRDT- 2019/03/30 06:00
PHST- 2019/03/04 00:00 [accepted]
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
PHST- 2019/03/28 00:00 [pmc-release]
AID - 10.1007/s11136-019-02163-3 [pii]
AID - 2163 [pii]
AID - 10.1007/s11136-019-02163-3 [doi]
PST - ppublish
SO  - Qual Life Res. 2019 Sep;28(9):2359-2372. doi: 10.1007/s11136-019-02163-3. Epub 
      2019 Mar 28.